Research Paper Volume 13, Issue 5 pp 7035—7051
ENAM gene associated with T classification and inhibits proliferation in renal clear cell carcinoma
- 1 Department of Urology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Huinan, Pudong, Shanghai 201399, China
- 2 The State Key Laboratory of Reproductive Medicine, Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
- 3 The First Clinical Medical College, Nanjing Medical University, Nanjing 211166, China
Received: November 4, 2020 Accepted: December 23, 2020 Published: February 3, 2021https://doi.org/10.18632/aging.202558
How to Cite
Copyright: © 2021 Ren et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The potential involvement of T classification-related genes in renal clear cell carcinoma (ccRCC) must be further explored. Public data were obtained from The Cancer Genome Atlas (TCGA) database. An overall survival (OS) predictive model was developed and validated (TCGA train, 5 years, AUC = 0.73, 3 years, AUC = 0.73, 1 year, AUC = 0.76; TCGA test, 5 years, AUC = 0.74, 3 years, AUC = 0.65, 1 year, AUC = 0.73; TCGA all, 5 years, AUC = 0.72, 3 years, AUC = 0.71, 1 year, AUC = 0.75). Finally, ENAM was selected for further analysis. In vitro experiment indicated that ENMA is downregulated in ccRCC, and its knockdown could promote proliferation in two cancer cell lines (OSRC-2 and SW839). Immune infiltration analysis revealed that ENAM could remarkably increase the content of cytotoxic cells, NK CD56 cells, NK cells and CD8+ T cells in the tumor immune microenvironment, which may be one reason for its tumor-inhibiting effect. In summary, ENAM may suppress cell proliferation in ccRCC and can be used as a potential reference value for the relief and immunotherapy of ccRCC.